Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Determination of acetyl coenzyme A in human whole blood by ultra-performance liquid chromatography-mass spectrometry.

Speziale R, Montesano C, De Leonibus ML, Bonelli F, Fezzardi P, Beconi MG, Monteagudo E, Elbaum D, Orsatti L.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Apr 15;1083:57-62. doi: 10.1016/j.jchromb.2018.02.039. Epub 2018 Mar 2.

PMID:
29524693
2.

Fosmetpantotenate (RE-024), a phosphopantothenate replacement therapy for pantothenate kinase-associated neurodegeneration: Mechanism of action and efficacy in nonclinical models.

Elbaum D, Beconi MG, Monteagudo E, Di Marco A, Quinton MS, Lyons KA, Vaino A, Harper S.

PLoS One. 2018 Mar 9;13(3):e0192028. doi: 10.1371/journal.pone.0192028. eCollection 2018.

3.

Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.

Toledo-Sherman LM, Prime ME, Mrzljak L, Beconi MG, Beresford A, Brookfield FA, Brown CJ, Cardaun I, Courtney SM, Dijkman U, Hamelin-Flegg E, Johnson PD, Kempf V, Lyons K, Matthews K, Mitchell WL, O'Connell C, Pena P, Powell K, Rassoulpour A, Reed L, Reindl W, Selvaratnam S, Friley WW, Weddell DA, Went NE, Wheelan P, Winkler C, Winkler D, Wityak J, Yarnold CJ, Yates D, Munoz-Sanjuan I, Dominguez C.

J Med Chem. 2015 Feb 12;58(3):1159-83. doi: 10.1021/jm501350y. Epub 2015 Jan 23.

PMID:
25590515
4.

The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease.

Beaumont V, Park L, Rassoulpour A, Dijkman U, Heikkinen T, Lehtimaki K, Kontkanen O, Al Nackkash R, Bates GP, Gleyzes M, Steidl E, Ramboz S, Murphy C, Beconi MG, Dominguez C, Munoz-Sanjuan I.

PLoS Curr. 2014 Feb 13;6. pii: ecurrents.hd.3304e87e460b4bb0dc519a29f4deccca. doi: 10.1371/currents.hd.3304e87e460b4bb0dc519a29f4deccca.

5.

Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048.

Beconi MG, Yates D, Lyons K, Matthews K, Clifton S, Mead T, Prime M, Winkler D, O'Connell C, Walter D, Toledo-Sherman L, Munoz-Sanjuan I, Dominguez C.

Drug Metab Dispos. 2012 Dec;40(12):2297-306. doi: 10.1124/dmd.112.046532. Epub 2012 Aug 31.

PMID:
22942319
6.

Pharmacokinetics of memantine in rats and mice.

Beconi MG, Howland D, Park L, Lyons K, Giuliano J, Dominguez C, Munoz-Sanjuan I, Pacifici R.

Version 2. PLoS Curr. 2011 Dec 15 [revised 2012 Jan 1];3:RRN1291.

7.

Identification, synthesis, and pharmacological evaluation of tetrahydroindazole based ligands as novel antituberculosis agents.

Guo S, Song Y, Huang Q, Yuan H, Wan B, Wang Y, He R, Beconi MG, Franzblau SG, Kozikowski AP.

J Med Chem. 2010 Jan 28;53(2):649-59. doi: 10.1021/jm901235p.

PMID:
20000470
8.

Fluoroolefins as amide bond mimics in dipeptidyl peptidase IV inhibitors.

Edmondson SD, Wei L, Xu J, Shang J, Xu S, Pang J, Chaudhary A, Dean DC, He H, Leiting B, Lyons KA, Patel RA, Patel SB, Scapin G, Wu JK, Beconi MG, Thornberry NA, Weber AE.

Bioorg Med Chem Lett. 2008 Apr 1;18(7):2409-13. doi: 10.1016/j.bmcl.2008.02.050. Epub 2008 Feb 26.

PMID:
18331795
9.

Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.

Beconi MG, Reed JR, Teffera Y, Xia YQ, Kochansky CJ, Liu DQ, Xu S, Elmore CS, Ciccotto S, Hora DF, Stearns RA, Vincent SH.

Drug Metab Dispos. 2007 Apr;35(4):525-32. Epub 2007 Jan 12.

PMID:
17220241
10.

Metabolic activation of a pentafluorophenylethylamine derivative: formation of glutathione conjugates in vitro in the rat.

Shang J, Xu S, Teffera Y, Doss GA, Stearns RA, Edmonson S, Beconi MG.

Xenobiotica. 2005 Jul;35(7):697-713.

PMID:
16316929
11.

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, Chan CC, Edmondson S, Feeney WP, He H, Ippolito DE, Kim D, Lyons KA, Ok HO, Patel RA, Petrov AN, Pryor KA, Qian X, Reigle L, Woods A, Wu JK, Zaller D, Zhang X, Zhu L, Weber AE, Thornberry NA.

Diabetes. 2005 Oct;54(10):2988-94.

12.

A semi-automated method for measuring the potential for protein covalent binding in drug discovery.

Day SH, Mao A, White R, Schulz-Utermoehl T, Miller R, Beconi MG.

J Pharmacol Toxicol Methods. 2005 Sep-Oct;52(2):278-85.

PMID:
16125627
13.

Metabolic activation of fluoropyrrolidine dipeptidyl peptidase-IV inhibitors by rat liver microsomes.

Xu S, Zhu B, Teffera Y, Pan DE, Caldwell CG, Doss G, Stearns RA, Evans DC, Beconi MG.

Drug Metab Dispos. 2005 Jan;33(1):121-30. Epub 2004 Oct 14.

PMID:
15486074
14.

Metabolism and pharmacokinetics of a dipeptidyl peptidase IV inhibitor in rats, dogs, and monkeys with selective carbamoyl glucuronidation of the primary amine in dogs.

Beconi MG, Mao A, Liu DQ, Kochansky C, Pereira T, Raab C, Pearson P, Lee Chiu SH.

Drug Metab Dispos. 2003 Oct;31(10):1269-77.

PMID:
12975337
15.

Use of on-line hydrogen/deuterium exchange to facilitate metabolite identification.

Liu DQ, Hop CE, Beconi MG, Mao A, Chiu SH.

Rapid Commun Mass Spectrom. 2001;15(19):1832-9. Erratum in: Rapid Commun Mass Spectrom. 2003;17(3):264..

PMID:
11565101
16.

Growth and subsequent feedlot performance of estradiol-implanted vs nonimplanted steers grazing fall-accumulated endophyte-infested or low-endophyte tall fescue.

Beconi MG, Howard MD, Forbes TD, Muntifering RB, Bradley NW, Ford MJ.

J Anim Sci. 1995 Jun;73(6):1576-84.

PMID:
7673051

Supplemental Content

Loading ...
Support Center